It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Moderna, Pfizer, AstraZeneca, and Johnson & Johnson are leading candidates for the completion of a Covid-19 vaccine likely to be released in the coming months. These companies have published their vaccine trial protocols. This unusually transparent action during a major drug trial deserves praise, close inspection of the protocols raises surprising concerns. These trials seem designed to prove their vaccines work, even if the measured effects are minimal.
WASHINGTON — When President Trump unveiled Operation Warp Speed in May, he declared that it was “unlike anything our country has seen since the Manhattan Project.”
The initiative — to accelerate the development of Covid-19 vaccines and therapeutics — lacks the scale, and the degree of secrecy, of the effort to build the atomic bomb. But Operation Warp Speed is largely an abstraction in Washington, with little known about who works there other than its top leaders, or how it operates. Even pharmaceutical companies hoping to offer help or partnerships have labored to figure out who to contact.
Now, an organizational chart of the $10 billion initiative, obtained by STAT, reveals the fullest picture yet of Operation Warp Speed: a highly structured organization in which military personnel vastly outnumber civilian scientists.
We are likely to need several Covid-19 vaccines to cover everyone and as a contingency, in case the virus mutates and “escapes” the ability of one vaccine to neutralise it, a real possibility in light of the discovery of an altered form of Sars-CoV-2 infecting European mink. But we also need better methods of diagnosing and treating the disease. The recent suspension of two major vaccine trials due to serious adverse events is a salutary reminder that there’s much still to learn and a pandemic, while no one would wish for one, provides scientists with a golden opportunity for learning.
"The impact of mutations in the SARS-CoV-2 S protein on viral infectivity and antigenicity have been assessed for eighty natural variants and twenty-six glycosylation spike variant strains using a pseudovirus assay . Most variants observed with amino acid change in the receptor binding domain were less infectious, while some variants - including A475V, L452R, V483A and F490L - were resistant to some neutralising antibodies.
We are likely to need several Covid-19 vaccines to cover everyone and as a contingency, in case the virus mutates and “escapes” the ability of one vaccine to neutralise it
originally posted by: PublicOpinion
a reply to: network dude
a reply to: elementalgrove
No, only rough differentiation like what we see in the articles.
I don't wanna mess with industrial espionage.
A recent, non-peer reviewed study from Imperial College London found that immunity to Covid-19 may decline over time, as levels of protective antibodies reportedly fell rapidly after infection.
However, according to Deepta Bhattacharya, an immunologist at the University of Arizona, there is emerging evidence that reinfections with common cold coronaviruses are a “result of viral genetic variations”, which may not be relevant to Sars-CoV-2.
a substance used to stimulate the production of antibodies and provide immunity against one or several diseases, prepared from the causative agent of a disease, its products, or a synthetic substitute, treated to act as an antigen without inducing the disease.
According to a protocol-based treatment algorithm, among hospitalized patients, use of hydroxychloroquine alone and in combination with azithromycin was associated with a significant reduction in-hospital mortality compared to not receiving hydroxychloroquine.
The study found that “the odds of hospitalisation of treated patients was 84% less than in the untreated patients,” and only one patient died from the group being treated with the drugs compared to 13 deaths in the untreated group.
Other early studies of hydroxychloroquine have reported conflicting results (Gao et al., 2020, Gautret et al., 2020b, Chen et al., 2020a, Tang et al., 2020, Chen et al., 2020b, Yu et al., 2020, Geleris et al., 2020, Rosenberg et al., 2020, Magagnoli et al., 2020, Million et al., 2020).